Biology before Anatomy in Early Breast Cancer — Precisely the Point
Author:
- 19 November 2015
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 373 (21) , 2079-2080
Abstract
Building on a foundation of clinical and laboratory observations, translational research, broad collaborations, and global education, adjuvant therapy for early-stage breast cancer has been an effective public health intervention. Standardization and even a one-size-fits-all philosophy were supported by individual trials and the worldwide overviews that showed proportional reductions in risk with chemotherapy in particular. Because higher risk, identified anatomically on the basis of tumor size or the presence of ipsilateral axillary nodal metastases, was associated with greater absolute therapeutic benefit, many clinical groups set risk thresholds, defined as a tumor size of 1 cm in the greatest dimension or any . . .Keywords
This publication has 8 references indexed in Scilit:
- Prospective Validation of a 21-Gene Expression Assay in Breast CancerNew England Journal of Medicine, 2015
- Breast Cancer Version 2.2015Journal of the National Comprehensive Cancer Network, 2015
- Impact of Oncotype DX Recurrence Score in the Management of Breast Cancer CasesClinical Breast Cancer, 2014
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe Lancet Oncology, 2010
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004